下载App
扫码立即下载
  • 下载App

    扫码立即下载

  • 在线客服

    登录后咨询在线客服
+
恭喜您!
成功领取价值超 5000港元/年的高级行情
前往体验 >>
多维分析
公司估值 资金追踪 卖空分析
09926 康方生物-B
20.300
-2.100-9.37%
显示同比
不显示
隐藏空行
(Q6)2022/06/30(FY)2021/12/31(Q6)2021/06/30(FY)2020/12/31
Per Share IndicaTor
Operating Cash Flow Per Share
-63.07% -0.831 -60.71% -1.4988 -81.38% -0.5096 -129.64% -0.9326
Cash Flow Per Share
-189.13% -0.6542 -99.67% 0.0086 -77.02% 0.734 57.66% 2.5737
Operating Income Per Share
23.43% 0.2335 -- 0.3378 -- 0.1892 -- --
Net Asset Per Share
-34.31% 3.733 -1.51% 4.7364 12.92% 5.6829 41030.79% 4.809
Basic Earning Per Share
-44.08% -0.9004 17.65% -1.6145 49.48% -0.6249 -- -1.9605
Diluted  Earning Per Share
-44.08% -0.9004 17.65% -1.6145 49.48% -0.6249 -- -1.9605
Profitability
Gross Profit Ratio
-17.23% 82.769% -- 86.146% -- 100.000% -- --
Operating Profit Ratio
-20.42% -414.414% -- -553.028% -- -344.128% -- --
Net Profit Ratio
-22.25% -424.117% -- -557.616% -- -346.939% -- --
Earning Before Tax Ratio
-22.25% -424.117% -- -557.616% -- -346.939% -- --
ROE
-75.83% -21.306% 53.6% -34.351% 67.47% -12.118% 50.8% -74.038%
ROA
-27.67% -12.597% 42.03% -25.139% 54.66% -9.867% -51.35% -43.370%
Yield Quality
Operating Cash To Total Revenue
-32.12% -355.947% -- -443.760% -- -269.411% -- --
Capital Structure
Debt Assets Ratio
222.39% 46.547% 201.7% 31.743% 30.46% 14.438% -87.92% 10.522%
Equity Multipler
53.74% 1.9101 25.47% 1.5189 0.42% 1.2424 -- 1.2105
Debt Equity Ratio
416.04% 87.080% 295.5% 46.506% 35.6% 16.874% -98.26% 11.759%
Current Assets To tatal Assets
-21.07% 59.731% -15.72% 65.593% -12.88% 75.678% 3.67% 77.832%
Non Current Assets To Total Assets
65.56% 40.269% 55.21% 34.407% 85.13% 24.322% -11.06% 22.168%
Current Liabilities To tatal Liabilities
57.75% 48.020% 2.6% 42.982% -34.5% 30.440% 409.74% 41.893%
Non Current Liabilities To Total Liabilities
-25.27% 51.980% -1.87% 57.018% 29.95% 69.560% -36.69% 58.107%
Solvency
Current Ratio
-84.48% 2.6723 -72.77% 4.8075 1.96% 17.2193 68.37% 17.6579
Quick Ratio
-85.59% 2.4018 -73.94% 4.5076 -0.57% 16.6647 67% 17.2976
Operating Profit To Current Liabilities
71.06% -0.6071 75.36% -1.903 32.15% -2.0977 -280.07% -7.7225
Operrating Cash Flow To Current Liabilities
68.25% -0.5214 57.99% -1.527 -87.19% -1.6422 -98.22% -3.6346
Share Equity Without Minority Interest To Total Liabilities
-79.82% 1.1248 -73.58% 2.0741 -23.67% 5.5746 180177.84% 7.8514
Operating Cash Flow To Total Liabilities
49.91% -0.2504 56.9% -0.6563 -22.61% -0.4999 -910.42% -1.5226
Operating Profit To Total Liabilities
54.34% -0.2915 74.72% -0.8179 55.56% -0.6385 -1837.38% -3.2351
Operating Capacity
Inventory Turnover(T)
-- 0.1109 -- 0.2441 -- -- -- --
Current Assets Turnover(T)
33.46% 0.052 -- 0.0744 -- 0.039 -- --
Fixed Assets Turnover(T)
-38.47% 0.1089 -- 0.2322 -- 0.177 -- --
Total Assets Turnover(T)
9.16% 0.0326 -- 0.0528 -- 0.0299 -- --
Growth Ability
Operating Revenue GR 3Y
-- -- -- 8456.169% -- 13776.802% -- --
Operating Profit GR 3Y
41.58% -408.258% 77.88% -781.434% -- -698.807% -- -3532.365%
EBT GR 3Y
48.41% -514.897% 94.37% -773.511% -- -998.008% -- -13745.543%
Net Profit GR 3Y
48.41% -514.897% 94.1% -773.511% -- -998.008% -- -13105.682%
Net Profit Attributable To The Parent Company GR 3Y
52.03% -484.731% 97.69% -709.501% -- -1010.562% -- -30704.677%
Total Assets GR 3Y
-- 719.803% 13.16% 688.406% -- -- -- 608.347%
Share Equity Without Minority Interest GR 3Y
-- 560.623% -9.6% 666.722% -- -- -- 737.505%
Equity GR 3Y
-- 492.883% -13.1% 618.538% -- -- -- 711.773%
Total Liabilities GR 3Y
-- 1362.702% 273.71% 896.826% -- -- -- 239.978%
Other Indicators
Currency Unit
港元港元港元港元

Q6、Q9、FY为累计季报:Q6 为中期报告;Q9 为第三季报;FY为年报。

环比数据来源于季报,环比 = (本期 - 上期)/上期 * 100%

公司概况 更多
康方生物科技(开曼)有限公司是一家主要从事生物产品研发的投资控股公司。该公司专注于满足肿瘤、免疫及其他治疗领域在全球的未决医疗需求。该公司的主要产品包括AK104、AK105、AK112及AK109。该公司于中国市场及海外市场开展业务。
董事长: 夏瑜
所属市场: 香港主板
上市日期: 2020/04/24
富途热股榜
港股美股沪深
交易热度搜索热度资讯热度
名称代码最新价涨跌幅

加载中...

自选
回到顶部